The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.

In relapsed/refractory DLBCL, the timing of relapse is a critical factor in determining the next line of therapy. Patients who relapse within 12 months are preferred candidates for CAR-T therapy. Those relapsing after 12 months may first undergo salvage chemotherapy followed by an autologous stem cell transplant if they respond.

A key conceptual shift is viewing ctDNA not as a statistical risk marker, but as direct detection of molecular residual disease (MRD). This framing, similar to how a CT scan identifies metastases, explains its high positive predictive value and justifies its use in making critical treatment decisions.

An exploratory strategy for DLBCL patients involves using ctDNA to detect minimal residual disease after CAR T-cell therapy. This allows for early intervention with bispecific antibodies when the disease burden is low, potentially preventing full clinical progression, a shift from reactive to proactive treatment.

Experts predict that emerging cell-free DNA (ctDNA) tests for lymphoma will shift treatment from fixed durations to a response-adapted approach. Monitoring minimal residual disease via ctDNA will allow clinicians to tailor the length of therapy based on the quality of response.

Both experts advocate shifting immune cell engager use from late-stage, high-burden cancer to a minimal residual disease (MRD) setting. Treating a low tumor load maximizes the effector-to-target ratio, enhances efficacy, and significantly reduces side effects, potentially moving these therapies to first-line combinations.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

Instead of competing with established therapies, Allogene is pioneering a "consolidation therapy" niche for its off-the-shelf CAR-T. It is targeting B cell lymphoma patients who are in remission but still test positive for minimal residual disease (MRD)—a high-risk group with an unmet need. This clinical strategy could create an entirely new market.

Instead of treating relapsed lymphoma, Allogene targets patients in remission who have Minimal Residual Disease (MRD), a molecular sign of future relapse. This "consolidation" strategy aims to prevent the cancer's return, a paradigm shift enabled by their therapy's high safety profile and sensitive MRD testing.